WEAVER GREGORY L

Average Profitability
<0.0001%
Insider Buys Quantity
8
Insider Buys Sum
$307,227.72
Insider Sells Quantity
3
Insider Sells Sum
$671,841.58

Insider Activity of WEAVER GREGORY L

According to the SEC Form 4 filings, WEAVER GREGORY L, being in a position of

  1. Chief Financial Officer at Altimmune, Inc.,
    оver the last 12 months, has bought 10000 shares for $51,996, and sold 0 shares,
    over all time since 2025-03-13, has bought 10000 shares for $51,996, and sold 0 shares.

The largest purchase of all time was on 2021-06-22 and amounted to 4666 shares of Atai Life Sciences N.V. for $69,990.

The largest sale of all time was on 2021-07-02 and amounted to 107497 shares of Atossa Therapeutics, Inc. for $599,833.

Biography of WEAVER GREGORY L

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$51,9961100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2025-03-13PurchaseAltimmune, Inc.
ALT
Chief Financial Officer
10,000
0.013%
$5.20$51,996+<0.01%
2023-11-15SaleAtossa Therapeutics, Inc.
ATOS
Former EVP, CFO, & Director
50,000
0.0395%
$0.65$32,500+103.08%
2023-06-20PurchaseAtossa Therapeutics, Inc.
ATOS
EVP & CFO
50,000
0.0401%
$0.97$48,500-1.19%
2021-07-02SaleAtossa Therapeutics, Inc.
ATOS
director
107,497
0.0883%
$5.58$599,833-69.09%
2021-06-22PurchaseAtai Life Sciences N.V.
ATAI
Chief Financial Officer
4,666
0.0028%
$15.00$69,990-57.97%
2013-11-21PurchaseAtossa Therapeutics, Inc.
ATOS
director
20,000
0.1359%
$2.58$51,570-30.41%
2013-03-19SaleImunon, Inc.
IMNN
CFO
37,272
0.3232%
$1.06$39,508-5.66%
2011-12-06PurchaseImunon, Inc.
IMNN
CFO
5,000
0.0879%
$2.15$10,750+5.42%
2011-05-26PurchaseImunon, Inc.
IMNN
director
8,636
0.1957%
$2.77$23,922-10.65%
2010-09-16PurchaseImunon, Inc.
IMNN
director
5,000
0.1268%
$3.10$15,500-6.11%
2007-02-23PurchaseImunon, Inc.
IMNN
director
10,000
0.2863%
$3.50$35,000+55.62%
Total: 11
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.